- Home
- SDHY vs DCTH Comparison
SDHY vs DCTH Comparison
Compare SDHY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- DCTH
- Stock Information
- Founded
- SDHY 2020
- DCTH 1988
- Country
- SDHY United States
- DCTH United States
- Employees
- SDHY N/A
- DCTH N/A
- Industry
- SDHY Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- SDHY Finance
- DCTH Health Care
- Exchange
- SDHY Nasdaq
- DCTH Nasdaq
- Market Cap
- SDHY 409.6M
- DCTH 388.3M
- IPO Year
- SDHY N/A
- DCTH N/A
- Fundamental
- Price
- SDHY $16.60
- DCTH $11.38
- Analyst Decision
- SDHY
- DCTH Strong Buy
- Analyst Count
- SDHY 0
- DCTH 4
- Target Price
- SDHY N/A
- DCTH $24.50
- AVG Volume (30 Days)
- SDHY 94.0K
- DCTH 742.8K
- Earning Date
- SDHY 01-01-0001
- DCTH 11-07-2025
- Dividend Yield
- SDHY 8.46%
- DCTH N/A
- EPS Growth
- SDHY N/A
- DCTH N/A
- EPS
- SDHY 1.07
- DCTH 0.06
- Revenue
- SDHY N/A
- DCTH $70,240,000.00
- Revenue This Year
- SDHY N/A
- DCTH $159.22
- Revenue Next Year
- SDHY N/A
- DCTH $42.78
- P/E Ratio
- SDHY $14.31
- DCTH $213.94
- Revenue Growth
- SDHY N/A
- DCTH 491.35
- 52 Week Low
- SDHY $13.93
- DCTH $8.87
- 52 Week High
- SDHY $15.50
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- SDHY 39.21
- DCTH 50.91
- Support Level
- SDHY $16.43
- DCTH $11.25
- Resistance Level
- SDHY $17.02
- DCTH $12.70
- Average True Range (ATR)
- SDHY 0.18
- DCTH 0.68
- MACD
- SDHY -0.03
- DCTH 0.10
- Stochastic Oscillator
- SDHY 24.58
- DCTH 38.43
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.